What is the all-cause mortality associated with tigecycline?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

All-Cause Mortality Associated with Tigecycline

Tigecycline is associated with increased all-cause mortality, with a 0.6% absolute risk increase (95% CI 0.1-1.2%) compared to comparator antibiotics, as documented in FDA meta-analyses and should be reserved only for situations when alternative treatments are not suitable. 1

FDA Black Box Warning

The FDA issued a black box warning based on a meta-analysis of 13 Phase 3 and 4 clinical trials showing death occurred in 4.0% (150/3,788) of tigecycline-treated patients versus 3.0% (110/3,646) of comparator-treated patients 1. This represents an adjusted risk difference of 0.6% (95% CI 0.1.2). The cause of this mortality difference has not been established, though deaths were generally attributed to worsening infection, complications, or underlying comorbidities 1.

Mortality by Infection Type

Hospital-Acquired and Ventilator-Associated Pneumonia

Particularly concerning mortality signals emerged in pneumonia:

  • Ventilator-associated pneumonia patients had 19.1% mortality with tigecycline versus 12.3% with comparators 1
  • Among VAP patients with bacteremia at baseline, mortality reached 50.0% (9/18) with tigecycline versus 7.7% (1/13) with comparators 1
  • Lower cure rates were observed: 47.9% versus 70.1% in clinically evaluable VAP patients 1

Carbapenem-Resistant Acinetobacter baumannii (CRAB)

For CRAB infections, tigecycline-based therapy showed:

  • 58 more deaths per 1,000 patients treated compared to colistin-based therapy (RR 1.12,95% CI 0.95-1.33) 2
  • 90 more clinical treatment failures per 1,000 patients (RR 1.17,95% CI 0.91-1.51) 2
  • However, evidence quality is very low, and differences may not be statistically significant 3

Carbapenem-Resistant Enterobacterales (CRE)

  • Tigecycline demonstrated inferiority to aminoglycosides for complicated urinary tract infections (moderate certainty evidence) 3
  • Two studies showed disadvantage compared to polymyxin-based regimens for CRE bloodstream infections 3
  • Low-certainty evidence suggests inferiority for cUTI and BSI caused by CRE 3

Independent Meta-Analyses Confirm Mortality Signal

A 2012 independent meta-analysis of 10 published and 3 unpublished RCTs (N=7,434) demonstrated:

  • Increased mortality: risk difference 0.7% (95% CI 0.1-1.2%, P=0.01) 4
  • Increased noncure rates: risk difference 2.9% (95% CI 0.6-5.2%, P=0.01) 4
  • Effects were not isolated to specific infection types or comparator regimens 4
  • The mortality signal was present even when limited to approved indications (RD 0.6%, P=0.04) 4

A 2011 Lancet meta-analysis of 14 trials (~7,400 patients) found:

  • All-cause mortality odds ratio of 1.28 (95% CI 0.97-1.69) favoring comparators, though not reaching statistical significance 5
  • Treatment success was lower with tigecycline (OR 0.87,95% CI 0.74-1.02) 5

Clinical Context and Dosing Considerations

Critical caveats:

  • Standard dosing (50 mg twice daily) may be inadequate for serious infections 3
  • High-dose regimens (200 mg loading, then 100 mg twice daily) should be used for HAP/VAP 3
  • Tigecycline efficacy correlates with MIC values: comparable to polymyxins when MIC ≤2 mg/L, inferior when MIC >2 mg/L 2
  • Tigecycline should be avoided in bacteremia and urinary tract infections due to poor pharmacokinetic penetration 3

Comparative Mortality with Other Agents

For CRAB infections, sulbactam-based therapy demonstrated:

  • Significantly lower 28-day mortality (adjusted HR 0.57,95% CI 0.34-0.94) compared to tigecycline 3
  • Lower ICU mortality (adjusted OR 0.12,95% CI 0.01-1.02) and treatment failure (adjusted OR 0.14,95% CI 0.04-0.55) 3

Safety Trade-offs

While tigecycline causes 225 fewer nephrotoxicity events per 1,000 patients compared to colistin (RR 0.23,95% CI 0.11-0.46) 2, this benefit must be weighed against the mortality signal. Gastrointestinal adverse events (nausea, vomiting, abdominal pain) are more common with tigecycline 2.

Guideline Recommendations

Both ESCMID (2022) and Asian guidelines (2023) recommend tigecycline only as part of combination therapy when alternatives are unsuitable 3, 2. The evidence consistently shows tigecycline should not be first-line therapy for serious MDR-GNB infections, particularly bacteremia and VAP, given the established mortality signal across multiple high-quality analyses.

References

4
Research

Excess deaths associated with tigecycline after approval based on noninferiority trials.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012

Related Questions

What loading dose does the Infectious Diseases Society of America (IDSA) 2026 edition recommend for tigecycline?
Is Clostridium perfringens susceptible to tigecycline?
How many days should tigecycline be administered for multidrug-resistant Escherichia coli causing emphysematous pyelonephritis?
How should tigecycline be administered intravenously, including dosing, infusion duration, and adjustments for hepatic impairment and pediatric patients?
Can tigecycline be given orally (by mouth)?
Does leptospirosis cause transaminitis or isolated hyperbilirubinemia?
What monitoring is required when initiating donepezil therapy?
What steps should be taken for a patient with suspected white‑coat hypertension and an office blood pressure of 170/100 mmHg, when the allied‑health examiner requires a blood pressure ≤150/80 mmHg for work‑related spirometry clearance?
Is clonidine appropriate for treating a hypertensive emergency, and what dosing regimen should be used?
What is the recommended acyclovir dosing regimen for Bell's palsy in adults and children?
Should spirometry be performed on a patient with an office blood pressure of 200/100 mmHg who has a confirmed diagnosis of white‑coat hypertension by ambulatory blood pressure monitoring?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.